Rosuvastatin induced gynecomastia: a rare presentation of newer statin


  • Suman Ruhela Medical Officer, SK Medical College and Hospital, Sikar, Rajasthan, India
  • Manish Ruhela Department of Cardiology, Noble Care Hospital, Sikar, Rajasthan, India
  • Rakesh Kumar Ola Department of Cardiology, Noble Care Hospital, Sikar, Rajasthan, India
  • Mahesh Rao Department of General Surgery, Noble Care Hospital, Sikar, Rajasthan, India



Rosuvastatin, Gynecomastia, Naranjo scale


Gynecomastia is a common benign disease characterized by the progressive enlargement of the glandular tissue of the male breast. The etiology may vary and may be physiological, pharmacological, pathological, or even idiopathic. Among men, drug induced gynecomastia may account for 10-20% of cases. Several case reports have associated this condition to the use of statins. However, there are few case reports of rosuvastatin induced gynecomastia have been reported in literature. We describe a 45-year-old male who developed bilateral gynecomastia after one month of rosuvastatin therapy, after switching to a different or less potent statin (atorvastatin), his symptoms resolved with-in one month. Use of the Naranjo adverse drug reaction probability scale indicated a possible relationship between the patient’s development of gynecomastia and rosuvastatin therapy.


Carlson HE. Gynecomastia. N Engl J Med. 1980;303:795-99.

Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007;357:1229-37.

Neuman JE. Evaluation and treatment of gynecomastia. Am Fam Physician. 1997;55:1835-44, 1849-50.

Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherap. 2012;32:1123-40.

Roberto G, Biagi C, Montanaro N, Koci A, Moretti U, Motola D. Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature. Eur J Clin Pharmacol. 2012;68:1007-11.

Smals AG. Gynecomastia. Neth J Med. 1987;31:47-51.

Peyriere H, Mauboussin JM, Rouanet I. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS. 1999;13:2167-9.

Hugues FC, Gourlot C, Le Jeunne C. Drug -induced gynecomastia. Ann Med Interne (Paris). 2000;151:10-7.

Uppsala Monitoring Centre. Vigibase online: the World Health Organization’s adverse drug reaction database. Accessed on 2 August, 2007.

Pfizer Ireland Pharmaceuticals. Lipitor (atorvastatin) package insert. Dublin, Ireland. 2004.

Novartis Pharmaceuticals Corporation. Lescol (fluvastatin) package insert. East Hanover, NJ. 2003.

Merck & Co., Inc. Mevacor (lovastatin) package insert. Whitehouse Station, NJ. 2005.

Hammons KB, Edwards RF, Rice WY. Golf-inhibiting gynecomastia associated with atorvastatin therapy. Pharmacotherap. 2006;26:1165-8.

Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003;1:495-50.

Astrazeneca SpA. Crestor (rosuvastatin) package insert. Basiglio, Italy. 2004.




How to Cite

Ruhela, S., Ruhela, M., Ola, R. K., & Rao, M. (2020). Rosuvastatin induced gynecomastia: a rare presentation of newer statin. International Journal of Basic & Clinical Pharmacology, 9(11), 1744–1745.



Case Reports